Search Results 2501-2510 of 20290 for Receptor

  1. Laboratories - Mayo Clinic Research

    Molecular Pharmacology of G Protein-Coupled Receptors: Laurence J. Miller · Motion Analysis: Kenton R. Kaufman · Movement Neurophysiology: John N. Caviness ...

  2. Neurology - Clinical trials - Mayo Clinic

    Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation ...

  3. Movement disorders - Doctors and departments - Mayo Clinic

    Andrew McKeon, M.B., B.Ch., M.D.. Neurologist. Rochester, MN. Areas of focus: Movement disorder, Dystonia, NMDA receptor antibody encephalitis, Myelin ...

  4. Clinical trials - Oncology (Medical)

    (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells.

  5. Radiopharmaceutical therapy shows favorable results for people with tough-to-treat meningioma brain tumors, Mayo Clinic study finds

    As nearly all meningiomas express somatostatin receptors, we evaluated the efficacy of lutetium-177 (177Lu)−Dotatate for refractory meningioma. Materials ...

  6. Neurology - Doctors - Mayo Clinic

    ... receptor antibody encephalitis, Autoimmune encephalitis, Normal pressure hydrocephalus, Wernicke-Korsakoff syndrome, Corticobasal syndrome. Show more areas ...

  7. A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

    Note: Participants receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study. Vaccination ...

  8. Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Mayo Clinic

    - Cytotoxic chemotherapy for any indication in last 2 years. - Prior use of selective estrogen receptor modulator (SERMS) or AIs including tamoxifen,

  9. MMRC Horizon One Adaptive Platform Trial Evaluating Therapies In RRMM - Mayo Clinic

    * Prior BCMA-directed antibody-drug conjugate (ADC) or chimeric antigen receptor (CAR)-T cell therapy allowed Note: A washout period of 6 months is required ...

  10. Infectious Diseases! Clinical Trials - Mayo Clinic Research

    This will be accomplished by utilizing the the immunoSEQ Human T-cell Receptor Beta (hsTCB) Assay (Adaptive Biothechnologies) and the publicly available ...